Autism Spectrum Disorder Treatment Market Share

Report ID: 5382
Published Date: Dec 06, 2024
Report Format: PDF, PPT

Buy Now

North America Market Forecast

North America industry is estimated to account for largest revenue share of 30% by 2037. The growth of the market in this region is due to the introduction and quick adoption of several autism medications. It is anticipated that the region's increased ASD research activity is expected to create new growth prospects. The United States has maintained a sizable market share in North America. The prevalence of autism spectrum diseases, rising R&D costs, and an increase in investment volume are the main drivers of market expansion. For example, according to a Centres for Disease Control and Prevention (CDC) update from March 2022, around 1 in 44 children has been diagnosed with autism spectrum disorder (ASD). As a result, the nation's need for treatment for autism spectrum disorders is rising. For example, F. Hoffmann-La Roche Ltd. started a clinical trial research in January 2020 in Toronto, Canada, for individuals with autism using the novel investigational medication Balovaptan. It is anticipated that the study's successful conclusion will stimulate market expansion.

Europe Market Statistics

Europe autism spectrum disorder treatment market is expected to hold 27% of the revenue share by 2037, owing to the rising R&D activity and a growing public awareness of autism. The growth of the market in this region is because of increased awareness and screening, easier access to assistance, and broader diagnostic criteria. Moreover, it is projected that throughout the projection period, increased product sales will strengthen the market in the area.

Browse key industry insights with market data tables & charts from the report:

Autism Spectrum Disorder Treatment Market Size & Share, Forecast Report 2037

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of gaming PC is estimated at USD 2.44 billion.

The autism spectrum disorder treatment market size was valued at USD 2.32 billion in 2024 and is likely to cross USD 5.13 billion by 2037, expanding at more than 6.3% CAGR during the forecast period i.e., between 2025-2037. Growing government efforts on raising funds and awareness for autism as well as increasing research and development will boost the market growth.

North America industry is estimated to account for largest revenue share of 30% by 2037, impelled by research & development in the region.

The major players in the market are Pfizer, Inc., Novartis AG, Curemark LLC, Yamo Pharmaceuticals, LLC, Merck & Co Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Bristol-Myer Squibb, Janssen Pharmaceuticals, Inc., Axial Therapeutics, Inc.